Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia

pharmanewsdaily- November 19, 2018 0

The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of ... Read More